Daré Bioscience Partners With MyMenopauseRx to Expand DARE to PLAY Access and Build a Women’s Health Ecosystem

Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven women’s health biotech company, announced a strategic collaboration with MyMenopauseRx on July 28, 2026, a telehealth platform focused exclusively on menopause care. The partnership features MyMenopauseRx as a telehealth option within the DARE Health Hub, giving women exploring DARE to PLAY access to board-certified menopause specialists alongside their prescription. Daré frames the collaboration as a foundation for additional strategic relationships and an expansion of its commercial strategy beyond product distribution into a broader women’s health ecosystem.

DARE to PLAY Addresses an Unmet Need With No FDA-Approved Competitor

DARE to PLAY is a topically applied sildenafil cream designed to improve female sexual arousal, launched commercially in December 2025 as a Section 503B compounded product. No FDA-approved pharmaceutical therapy currently exists for female sexual arousal disorder, making DARE to PLAY the first clinically studied, formulation-specific option women can access through a licensed clinician. Pre-fulfillment prescribing became available in all 50 states on February 11, 2026, with telehealth access enabling prescriptions without an in-person visit. Dispensing through Medvantx fulfillment infrastructure is targeted to commence later in summer 2026. The ACOG annual conference in Q1 2026 generated strong interest from the healthcare provider community, reinforcing Daré’s view that clinician advocacy will drive commercial momentum as awareness builds.

MyMenopauseRx Fills the Clinical Context Gap

The partnership reflects a practical commercial insight. Women exploring DARE to PLAY often sit within a broader perimenopause or menopause experience, where changes in arousal coexist with disrupted sleep, mood shifts, cognitive changes, and energy loss. A product-only access model leaves that broader clinical need unaddressed, which can limit both conversion and retention. By featuring MyMenopauseRx as an integrated telehealth option inside the DARE Health Hub, Daré connects women who want DARE to PLAY with specialists qualified to address the full menopause picture in a single engagement. CEO Sabrina Martucci Johnson described the collaboration as ensuring women do not have to navigate menopause alone or shoulder the search for a knowledgeable provider themselves. The asset-light commercial model Daré operates, built around targeted digital awareness and infrastructure partnerships rather than a large internal salesforce, makes this kind of collaboration a natural and capital-efficient growth lever.

A Pipeline Behind the Commercial Launch Extends the Investment Thesis

Beyond DARE to PLAY, Daré advances a pipeline of women’s health candidates across contraception, menopause, and infectious disease. Ovaprene, a hormone-free monthly intravaginal contraceptive, is in a pivotal Phase 3 study, with enrollment completion targeted for late 2026 and data expected in 2027. Daré to RESTORE, a consumer vaginal probiotic line, represents the company’s first over-the-counter revenue stream. DARE-HPV, a Phase 2 program targeting the approximately 6 million U.S. women annually who acquire high-risk HPV strains, is fully funded through an ARPA-H contract, with top-line data expected in 2026. DARE to RECLAIM, a combination estradiol and progesterone vaginal ring designed to be the first non-oral form combining both hormones, targets 503B compounded availability in 2027. The MyMenopauseRx collaboration ties directly into this pipeline by building the clinical relationships and ecosystem infrastructure that could support multiple product launches as each candidate reaches market.

Strategic Investment Summary

• MyMenopauseRx Collaboration: Daré Bioscience (NASDAQ: DARE) launched a strategic collaboration with MyMenopauseRx on July 28, 2026, featuring the menopause telehealth platform as an integrated option within the DARE Health Hub for women exploring DARE to PLAY.
• DARE to PLAY Status: The first clinically studied topical sildenafil cream for female sexual arousal launched commercially in December 2025, with nationwide prescribing available since February 2026 and dispensing through Medvantx commencing summer 2026.
• Unmet Need: No FDA-approved pharmaceutical treatment for female sexual arousal disorder currently exists, giving DARE to PLAY a clear first-mover position as a formulation-specific, clinician-prescribed option in a condition affecting millions of women.
• Commercial Model: Daré runs an asset-light commercialization model built on targeted digital awareness, telehealth infrastructure, and Medvantx fulfillment, with strategic collaborations like MyMenopauseRx serving as capital-efficient channels to expand reach.
• Pipeline Depth: Near-term catalysts include DARE-HPV top-line data in 2026 (ARPA-H funded), Ovaprene Phase 3 enrollment completion in late 2026, and DARE to RECLAIM 503B availability in 2027.
• Ecosystem Strategy: Daré frames the MyMenopauseRx deal as the foundation for additional strategic relationships, building a women’s health ecosystem connecting products, clinical expertise, and access to care across multiple indications.

Find out more about the latest corporate developments and financial reports at the Daré Bioscience investor portal.